Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Real-World Venetoclax-Obinutuzumab in 232 Treatment Naive CLL Patients: Feasibility and Tolerability

Blood (2023) 142 (Supplement 1): 4646.

https://doi.org/10.1182/blood-2023-186182

Published: 2023

Journal Articles

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Blood (2023) 142 (Supplement 1): 1905.

https://doi.org/10.1182/blood-2023-181597

Published: 2023

Journal Articles

Pet-2 Positive during Frontline Therapy: An Early Unfavorable Predictor for Subsequent Salvage High-Dose Chemotherapy (HD-CT) and Autologous Stem Cell Transplant in Relapsed or Refractory Classical Hodgkin Lymphoma

Blood (2023) 142 (Supplement 1): 6179.

https://doi.org/10.1182/blood-2023-173085

Published: 2023

Journal Articles

A Radiation-Free Approach Based on the Whole-Body-MRI Has Shown a High Level of Accuracy in the Follow up of Lymphoma Patients. a Single Center Retrospective Study

Antonio Frolli, Silvia Varvello, Annalisa Balbo Mussetto, Daniela Gottardi, Martina Bullo, Silvia Marini, Giuseppe Saglio, Stefano Cirillo, Daniela Cilloni, Guido Eugenio Parvis

Blood (2022) 140 (Supplement 1): 9317.

https://doi.org/10.1182/blood-2022-168519

Published: 2022

Journal Articles

Lesion Dissemination in Baseline PET/CT (D-MAX) and IPS Score Predict ABVD Treatment Outcome in PET-2 Negative Advanced-Stage Hodgkin Lymphoma Patients Enrolled in the Prospective GITIL/FIL HD0607 Trial

Blood (2021) 138 (Supplement 1): 2443.

https://doi.org/10.1182/blood-2021-152292

Published: 2021

Journal Articles

Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'

Francesca Romana Mauro, MD PhD, Gianluigi Reda, MD, Valentina Arena, MS, Livio Trentin, MD, Marta Coscia, MD PhD, Paolo Sportoletti, MD, Luca Laurenti, MD, Gianluca Gaidano, Roberto Marasca, MD, Lorella Orsucci, MD, Roberta Murru, MD, Caterina Stelitano, Fiorella Ilariucci, MD, Donato Mannina, MD, Massimo Massaia, MD, Gian Matteo Rigolin, Lydia Scarfo, Monia Marchetti, MD, Luciano Levato, MD, Monica Tani, MD, Annalisa Arcari, MD, Gerardo Musuraca, MD, Marina Deodato, Piero Galieni, Catello Califano, MD, Daniela Gottardi, MD, Anna Marina Liberati, MD, Daniela Pietrasanta, MD, Stefano Molica, MD, Ramona Cassin, MD, Andrea Visentin, MDPhD, Candida Vitale, MDPhD, Gianfranco Lapietra, MD, Irene Della Starza, PhD, Maria Stefania De Propris, PhD, Sara Raponi, PhD, Mauro Nanni, PhD, Ilaria Del Giudice, MD PhD, Giorgia Giuliani, PhD, Marco Vignetti, MD, Anna Guarini, PhD, Francesco Albano, Antonino Neri, MD, Antonio Cuneo, MD, Robin Foà, MD

Blood (2020) 136 (Supplement 1): 47–49.

https://doi.org/10.1182/blood-2020-135922

Published: 2020

Journal Articles

B-ALL/NHL 2002 GMALL Protocol As First-Line Treatment in Patients with Double-Hit Lymphoma: Favorable Results in18 Consecutive Patients from Two Italian Institutions

Safaa M. Ramadan, PhD MD, Alessandro Cignetti, MD PhD, Simona Sammassimo, MD, Enrico Derenzini, MD PhD, Giusy Ceparano, MD, Tommaso Radice, MD, Federica Gigli, MD, Stefano Fiori, MD, Valentina Tabanelli, MD, Martina Milani, Emanuela Omodeo Sale', Sara Gandini, PhD, Daniela Gottardi, MD, Giuseppe Saglio, MD, Stefano Pileri, MD, Corrado Tarella, MD

Blood (2019) 134 (Supplement_1): 1631.

https://doi.org/10.1182/blood-2019-128794

Published: 2019

Journal Articles

Prognostic Impact of the Baseline Immunologic Profile in Patients with Aggressive B Non-Hodgkin Lymphomas

Safaa M. Ramadan, PhD MD, Giusy Ceparano, MD, Alessandro Cignetti, MD PhD, Simona Sammassimo, MD, Vincenzo Bagnardi, Eleonora Pagan, Daniela Gottardi, MD, Stefano Fiori, MD, Rita Passerini, Tommaso Radice, MD, Giuseppe Saglio, MD, Corrado Tarella, MD

Blood (2019) 134 (Supplement_1): 1522.

https://doi.org/10.1182/blood-2019-132237

Published: 2019

Journal Articles

Low Circulating B Lymphocytes in Newly Diagnosed Follicular and Diffuse Large B Cell Lymphoma: Differences Compared to Normal Subjects and Possible Prognostic Role

Riccardo Bruna, Massimo Geuna, Delia Rota Scalabrini, MD, Alessandro Cignetti, MD PhD, Nathalie Santoro, Daniela Gottardi, MD, Roberto Passera, Corrado Tarella, MD Prof

Blood (2017) 130 (Supplement 1): 1482.

https://doi.org/10.1182/blood.V130.Suppl_1.1482.1482

Published: 2017

Journal Articles

Early Reduction of Serum TARC Levels Predicts Prognosis of Patients Treated with a PET-Adapted Strategy for Advanced Stage Hodgkin Lymphoma (HL) in the GITIL/FIL HD0607 Trial

Blood (2017) 130 (Supplement 1): 1511.

https://doi.org/10.1182/blood.V130.Suppl_1.1511.1511

Published: 2017

Journal Articles

Life Expectancy in Follicular Lymphoma Is Mainly Determined By Response to First LINE Treatment: A LONG-TERM Survey on 597 Patients

Corrado Tarella, MD, Angela Gueli, Federica Delaini, Anna Maria Barbui, MD, Riccardo Bruna, Daniele Caracciolo, Daniela Gottardi, Giuseppe Gritti, MD, Roberto Passera, PharmD, PhD, Safaa Ramadan, PhD MD, Andrea Rossi, MD, Alessandro Rambaldi, MD

Blood (2015) 126 (23): 3989.

https://doi.org/10.1182/blood.V126.23.3989.3989

Published: 2015

Journal Articles

Whole Body Magnetic Resonance Imaging with Diffusion Weighted Imaging Is a Valuable Alternative to Contrast-Enhanced Computed Tomography for the Initial Staging in Hodgkin’s and Non-Hodgkin’s Lymphoma

Annalisa Balbo-Musetto, MD, Riccardo Bruna, MD, Angela Gueli, MD, Chiara Saviolo, MD, Massimo Petracchini, MD, Daniela Gottardi, MD, Alberto De Crescenzo, MD, Stefano Cirillo, MD, Corrado Tarella, MD

Blood (2014) 124 (21): 1278.

https://doi.org/10.1182/blood.V124.21.1278.1278

Published: 2014

Journal Articles

Primary Refractory Disease in Non-Hodgkin's Lymphoma: A Retrospective Study On 3,952 Newly Diagnosed Patients Undergoing First-Line Chemotherapy

Corrado Tarella, MD, Angela Gueli, MD, Federica Delaini, BiolSC, Andrea Rossi, MD, Anna Maria Barbui, MD, Giuseppe Gritti, MD, Daniele Caracciolo, Huijing Hu, MD, Daniela Gottardi, MD, Roberto Passera, PharmD PhD, Alessandro Rambaldi, MD

Blood (2012) 120 (21): 305.

https://doi.org/10.1182/blood.V120.21.305.305

Published: 2012

Journal Articles

Overall Survival Benefit for Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance with Bortezomib-Thalidomide (VMPT-VT) Versus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients

Blood (2012) 120 (21): 200.

https://doi.org/10.1182/blood.V120.21.200.200

Published: 2012

Journal Articles

Early and Permanent Telomere Shortening in Bone Marrow-Derived Cells Following Chemotherapy: A Parallel Study In Vivo in Lymphoma Patients and In Vitro in Cultured Mesenchymal Stem Cells

Angela Gueli, MD, Marco Ruella, MD, Alessandra Risso, PhD, Tiziana Spatola, PhD, Hui Jing Hu, MD, Daniela Gottardi, MD, Alberto De Crescenzo, MD, Stefano Buttiglieri, PhD, Corrado Tarella, MD

Blood (2011) 118 (21): 1620.

https://doi.org/10.1182/blood.V118.21.1620.1620

Published: 2011

Journal Articles

Bortezomib-Based Induction Treatments Improve Outcomes of Newly Diagnosed Multiple Myeloma Patients with High-Risk Cytogenetic Abnormalities

Blood (2010) 116 (21): 781.

https://doi.org/10.1182/blood.V116.21.781.781

Published: 2010

Journal Articles

Nicotinamide Promotes Apoptosis In Chronic Lymphocytic Leukemia through Activation of the p53/Mir-34a/SIRT1 Tumor Suppressor Network

Valentina Audrito, Tiziana Vaisitti, Sara Serra, Davide Rossi, Daniela Gottardi, Giovanni D’Arena, Gianluca Gaidano, Fabio Malavasi, Silvia Deaglio

Blood (2010) 116 (21): 4627.

https://doi.org/10.1182/blood.V116.21.4627.4627

Published: 2010

Journal Articles

Lenalidomide as Single Agent to Control Minimal Residual Disease in Chronic Lymphocytic Leukemia In First Complete Remission: Report of Three cases

Alberto De Crescenzo, MD, Marco Ruella, MD, Daniela Gottardi, MD, Giuseppina Prato, PhD, Massimo Geuna, PhD, Angela Gueli, MD, Corrado Tarella, MD

Blood (2010) 116 (21): 4640.

https://doi.org/10.1182/blood.V116.21.4640.4640

Published: 2010

Journal Articles

Efficacy and Safety of Once Weekly Bortezomib In Multiple Myeloma Patients

Blood (2010) 116 (21): 3029.

https://doi.org/10.1182/blood.V116.21.3029.3029

Published: 2010

Journal Articles

Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Followed by Maintenance with Bortezomib and Thalidomide for Initial Treatment of Elderly Multiple Myeloma Patients.

Blood (2009) 114 (22): 128.

https://doi.org/10.1182/blood.V114.22.128.128

Published: 2009

NARROW

Real-World Venetoclax-Obinutuzumab in 232 Treatment Naive CLL Patients: Feasibility and Tolerability

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Pet-2 Positive during Frontline Therapy: An Early Unfavorable Predictor for Subsequent Salvage High-Dose Chemotherapy (HD-CT) and Autologous Stem Cell Transplant in Relapsed or Refractory Classical Hodgkin Lymphoma

A Radiation-Free Approach Based on the Whole-Body-MRI Has Shown a High Level of Accuracy in the Follow up of Lymphoma Patients. a Single Center Retrospective Study

Lesion Dissemination in Baseline PET/CT (D-MAX) and IPS Score Predict ABVD Treatment Outcome in PET-2 Negative Advanced-Stage Hodgkin Lymphoma Patients Enrolled in the Prospective GITIL/FIL HD0607 Trial

Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'

B-ALL/NHL 2002 GMALL Protocol As First-Line Treatment in Patients with Double-Hit Lymphoma: Favorable Results in18 Consecutive Patients from Two Italian Institutions

Prognostic Impact of the Baseline Immunologic Profile in Patients with Aggressive B Non-Hodgkin Lymphomas

Low Circulating B Lymphocytes in Newly Diagnosed Follicular and Diffuse Large B Cell Lymphoma: Differences Compared to Normal Subjects and Possible Prognostic Role

Early Reduction of Serum TARC Levels Predicts Prognosis of Patients Treated with a PET-Adapted Strategy for Advanced Stage Hodgkin Lymphoma (HL) in the GITIL/FIL HD0607 Trial

Life Expectancy in Follicular Lymphoma Is Mainly Determined By Response to First LINE Treatment: A LONG-TERM Survey on 597 Patients

Whole Body Magnetic Resonance Imaging with Diffusion Weighted Imaging Is a Valuable Alternative to Contrast-Enhanced Computed Tomography for the Initial Staging in Hodgkin’s and Non-Hodgkin’s Lymphoma

Primary Refractory Disease in Non-Hodgkin's Lymphoma: A Retrospective Study On 3,952 Newly Diagnosed Patients Undergoing First-Line Chemotherapy

Overall Survival Benefit for Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance with Bortezomib-Thalidomide (VMPT-VT) Versus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients

Early and Permanent Telomere Shortening in Bone Marrow-Derived Cells Following Chemotherapy: A Parallel Study In Vivo in Lymphoma Patients and In Vitro in Cultured Mesenchymal Stem Cells

Bortezomib-Based Induction Treatments Improve Outcomes of Newly Diagnosed Multiple Myeloma Patients with High-Risk Cytogenetic Abnormalities

Nicotinamide Promotes Apoptosis In Chronic Lymphocytic Leukemia through Activation of the p53/Mir-34a/SIRT1 Tumor Suppressor Network

Lenalidomide as Single Agent to Control Minimal Residual Disease in Chronic Lymphocytic Leukemia In First Complete Remission: Report of Three cases

Efficacy and Safety of Once Weekly Bortezomib In Multiple Myeloma Patients

Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Followed by Maintenance with Bortezomib and Thalidomide for Initial Treatment of Elderly Multiple Myeloma Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only